October – 03 November 2020
PFIZER EDUCATIONAL PROGRAM
STATISTICS IN PHARMACEUTICAL R&D
· Motivation & Summarizing Data
· Measures of Effect
· Confounding
· Simple Analysis
ONLINE
(broadcast links provided)
Уважаемые студенты фармацевтических специальностей. Мы приглашаем вас принять участие в осеннем образовательном модуле компании Pfizer, который будет посвящен разработке и использовании статистических методов при проведении научных исследований в фармацевтике. Ведущие зарубежные научные сотрудники Pfizer из главных исследовательских центров компании расскажут об основных инструментах для анализа экспериментальных данных и результатов исследований, поделятся практическим опытом применения биостатистики при разработке инновационных лекарственных препаратов.
С 2012 года Pfizer реализует комплексную образовательную программу для развития и повышения квалификации студентов профильных вузов. Программа образовательных модулей формируется на основе актуальных потребностей отрасли. Лекции проводят международные и российские эксперты, работающие на производственных и научно-исследовательских площадках Pfizer по всему миру. Стратегический партнер образовательной программы Pfizer – Санкт-Петербургский химико-фармацевтический университет.
Лекции Осеннего образовательного модуля Pfizer будут проходить на английском языке.
Pfizer Educational program
Time Zone «Moscow GMT +3»
TUESDAY, OCT 20, 2020
16:00 – 17:30 MOTIVATION & SUMMARIZING DATA
· Alex Ostrowski, Sr. Statistical Programmer, Pfizer (USA)
Event address for attendees: https://pfizerevents.webex.com/pfizerevents/onstage/g.php?MTID=ef52f633a417f64e7b3271fabcfb20769
Event number: 145 770 3695
Event password: fV3mAZBwq54
THURSDAY, OCT 22, 2020
MEASURES OF EFFECT
· Joseph Cappelleri, Executive Director of Biostatistics, Statistical Research and Data Science Center, Pfizer (USA)
Event address for attendees: https://pfizerevents.webex.com/pfizerevents/onstage/g.php?MTID=e9c6d28165f9ab3241a7344b4d14e1919
Event number: 145 115 3297
Event password: 362eM6hcEgp
TUESDAY, OCT 27, 2020
CONFOUNDING
· David Gruben, Sr. Director, Statistics, Pfizer (USA)
Event address for attendees: https://pfizerevents.webex.com/pfizerevents/onstage/g.php?MTID=ec47c12a1a8dd56381c647174017d9955
Event number: 145 659 5323
Event password: 2Yt8Q8FtKJK
TUESDAY, NOV 03, 2020
SIMPLE ANALYSIS
· Joseph Cappelleri, Executive Director of Biostatistics, Statistical Research and Data Science Center, Pfizer (USA)
Event address for attendees: TBI
Event number: TBI
Event password: TBI
Biography
Alex Ostrowski, Pfizer
Prior to Pharmaceuticals worked in food manufacturing specializing in FDA audits and compliance. Worked closely with Research and Development to design new products and establish automation projects under HACCP requirements. Exited this industry to further seek education and experience in areas of interest; specifically, statistics and programming. Worked as a Data Analyst Manager, with a team of 14 direct reports, at another large Pharmaceutical company prior to joining Pfizer. Since joining Pfizer, he has worked on multiple assets in the Rare Disease, Biosimilars, and Hospital Brands team space.
Earned dual master’s degree from Villanova in Statistics and Mathematics and currently teach in the evening at Penn State University.
Joseph Cappelleri, Pfizer
Joseph C. Cappelleri earned his MS in statistics from the City University of New York (Baruch College), PhD in psychometrics from Cornell University, MPH in epidemiology from Harvard University. Dr. Cappelleri is an executive director of biostatistics in the Statistical Research and Data Science Center at Pfizer Inc, where he is the recipient of the Craig A. Saxton Clinical Development Excellence Award and partners with colleagues in Patient & Health Impact and Medical Affairs. As an adjunct professor, he has served on the faculties at Brown University (biostatistics), Tufts Medical Center (medicine), and the University of Connecticut (statistics). He has co-authored approximately 1000 external presentations and 500 publications on clinical and methodological topics, including on regression-discontinuity designs, meta-analysis, and health measurement scales. Dr. Cappelleri is the lead author of the book “Patient-Reported Outcomes: Measurement, Implementation and Interpretation” and has co-authored or co-edited three other books (one on subgroup design and analysis, one on Phase II clinical development of new drugs, and another on health economics and outcomes research). He is a Fellow of the American Statistical Association.
David Gruben, Pfizer
David’s career has focused on working in diseases involving inflammation, cardiovascular, gastro-intestinal and dermatology that are investigated in randomized, clinical trials. Most recently he is supporting the Pfizer medication used in treating inflammation and gastro-intestinal diseases in terms of market access, that is, approval by countries throughout the world. This involves post-hoc analyses of clinical trial data, as well as analyses of new data to be found in treatment registries, and data based on payment records that insurance companies keep. This is for answering questions that arise in the real-world treatment of patients. These kinds of analyses pave the way for next generation of medications that Pfizer may be developing in these indications.
In addition to Pfizer Davis has worked at two major pharmaceutical companies and one medical school. Ph.D. from Temple University in Philadelphia, Pennsylvania, USA.